Ivan Kairatov has spent years at the intersection of structural biology and biopharma, translating difficult, dynamic molecules into practical insights that can power new therapeutics. In this conversation, he unpacks a “molecular film” of a self-splicing ribozyme—captured almost frame by frame—and
Families and clinicians have long wrestled with the same question: when choices span medication, therapy, and a dozen hopeful alternatives, which option is most likely to help right now without creating new problems later, and how confident should anyone be in that promise. That recurring
Dementia’s slow drift can feel inevitable for families and clinicians, yet the difference between spotting subtle decline early and recognizing it late often spells a shift from measured planning to crisis response with consequences that ripple through lives and budgets alike. EEG stands out as a
Every sentence you hear arrives as an unbroken ribbon of sound, yet your mind carves it into words with split-second precision before the next syllable even lands, never waiting for a pause that does not exist. That everyday magic—effortless for a native tongue and baffling in an unfamiliar
The scale of diabetic eye screening would swamp any manual system left to grow unchecked, with more than four million people eligible in England and tens of millions of images flowing through a pipeline that still leans on multiple human graders per case to keep patients safe and services moving.
Glioblastoma care has long run up against a biological wall that blunts even the best therapies, and a new approach that pries open that wall just long enough to let drugs in now looks like a genuine shift rather than a lab curiosity. Patients still face a dire prognosis despite aggressive surgery
